Division of Urology, San Luigi Gonzaga Hospital, University of Turin, Orbassano, Italy; Department of Urology, Cleveland Clinic, Cleveland, OH, USA.
Division of Urology, Department of Surgery, Virginia Commonwealth University Health System, Richmond, VA, USA.
Eur Urol. 2018 Aug;74(2):226-232. doi: 10.1016/j.eururo.2018.05.004. Epub 2018 May 19.
While partial nephrectomy (PN) represents the standard surgical management for cT1 renal masses, its role for cT2 tumors is controversial. Robot-assisted PN (RAPN) is being increasingly implemented worldwide.
To analyze perioperative, functional, and oncological outcomes of RAPN for cT2 tumors.
DESIGN, SETTING, AND PARTICIPANTS: Retrospective analysis of a large multicenter, multinational dataset of patients with nonmetastatic cT2 masses treated with robotic surgery (ROSULA: RObotic SUrgery for LArge renal mass).
Robotic-assisted PN.
Patients' demographics, lesion characteristics, perioperative variables, renal functional data, pathology, and oncological data were analyzed. Univariable and multivariable regression analyses assessed the relationships with the risk of intra-/postoperative complications, recurrence, and survival.
A total of 298 patients were analyzed. Median tumor size was 7.6 (7-8.5) cm. Median RENAL score was 9 (8-10). Median ischemia time was 25 (20-32) min. Median estimated blood loss was 150 (100-300) ml. Sixteen patients had intraoperative complications (5.4%), whereas 66 (22%) had postoperative complications (5% were Clavien grade ≥3). Multivariable analysis revealed that a lower RENAL score (odds ratio [OR] 0.46, 95% confidence interval [CI] 0.21-0.65, p=0.02) and pathological pT2 stage (OR 0.51, 95% CI 0.12-0.86, p=0.001) were protective against postoperative complications. A total of 243 lesions (82%) were malignant. Twenty patients (8%) had positive surgical margins. Ten deaths and 25 recurrences/metastases occurred at a median follow-up of 12 (5-35) mo. At univariable analysis, higher pT stage was predictive of a likelihood of recurrences/metastases (p=0.048). While there was a significant deterioration of renal function at discharge, this remained stable over time at 1-yr follow-up. The main limitation of this study is its retrospective design.
RAPN in the setting of select cT2 renal masses can safely be performed with acceptable outcomes. Further studies are warranted to corroborate our findings and to better define the role of robotic nephron sparing for this challenging indication.
This report shows that robotic surgery can be used for safe removal of a large renal tumor in a minimally invasive fashion, maximizing preservation of renal function, and without compromising cancer control.
虽然部分肾切除术(PN)是治疗 cT1 肾肿瘤的标准手术治疗方法,但对于 cT2 肿瘤,其作用仍存在争议。机器人辅助 PN(RAPN)在全球范围内得到了越来越多的应用。
分析 RAPN 治疗 cT2 肿瘤的围手术期、功能和肿瘤学结果。
设计、地点和参与者:回顾性分析了一个大型多中心、多国非转移性 cT2 肿块患者的机器人手术数据集(ROSULA:机器人手术治疗大肾肿块)。
机器人辅助 PN。
分析了患者的人口统计学、病变特征、围手术期变量、肾功能数据、病理和肿瘤学数据。单变量和多变量回归分析评估了与术中/术后并发症、复发和生存风险的关系。
共分析了 298 例患者。中位肿瘤大小为 7.6(7-8.5)cm。中位 RENAL 评分为 9(8-10)。中位缺血时间为 25(20-32)min。中位估计失血量为 150(100-300)ml。16 例患者发生术中并发症(5.4%),66 例(22%)发生术后并发症(5%为 Clavien 分级≥3)。多变量分析显示,较低的 RENAL 评分(比值比[OR]0.46,95%置信区间[CI]0.21-0.65,p=0.02)和病理 pT2 期(OR 0.51,95%CI 0.12-0.86,p=0.001)是术后并发症的保护因素。243 个病灶(82%)为恶性。20 例(8%)患者切缘阳性。在中位随访 12(5-35)mo 时,有 10 例死亡和 25 例复发/转移。单变量分析显示,较高的 pT 分期是复发/转移的预测因素(p=0.048)。虽然出院时肾功能有明显恶化,但在 1 年随访时保持稳定。本研究的主要局限性是其回顾性设计。
在选择的 cT2 肾肿瘤患者中,RAPN 可以安全进行,具有可接受的结果。需要进一步的研究来证实我们的发现,并更好地定义机器人肾部分切除术在这一具有挑战性适应症中的作用。
本报告表明,机器人手术可以安全地微创切除大型肾肿瘤,最大限度地保留肾功能,同时不影响癌症控制。